XML 62 R26.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Stock-Based Compensation (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2015 | Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] |  | AntriaBio has computed the fair value of all options granted during the year ended June 30, 2014 using the following assumptions:
Expected volatility |  | 94 | %
Risk free interest rate |  | 2.16% - 2.26 | %
Expected term (years) |  | 7 |
Dividend yield |  | 0 | %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Stock option activity is as follows:
|  |  |  |  | Weighted |  | Weighted Average |
|  | Number of |  | Average |  | Remaining |
|  | Options |  | Exercise Price |  | Contractual Life |
Outstanding, June 30, 2013 |  |  | 1,508,334 |  | $ | 4.50 |  |  | 4.6 |
Granted |  |  | 2,835,000 |  | $ | 3.14 |  |  |  |
Outstanding, June 30, 2014 |  |  | 4,343,334 |  | $ | 3.61 |  |  | 5.6 |
Granted |  |  | 4,532,000 |  | $ | 2.03 |  |  |  |
Forfeited |  |  | (212,916) |  | $ | 3.57 |  |  |  |
Outstanding, March 31, 2015 |  |  | 8,662,418 |  | $ | 2.78 |  |  | 7.4 |
Exercisable at March 31, 2015 |  |  | 2,065,147 |  | $ | 3.95 |  |  | 4.1 |
| Stock option activity is as follows:
|  |  |  | Weighted |  | Weighted Average |
|  | Number of |  | Average |  | Remaining |
|  | Options |  | Exercise Price |  | Contractual Life |
Outstanding, June 30, 2012 |  | - |  | $ | - |  | - |
Granted |  | 1,508,334 |  | $ | 4.50 |  |  |
Outstanding, June 30, 2013 |  | 1,508,334 |  | $ | 4.50 |  | 4.6 |
Granted |  | 2,835,000 |  | $ | 3.14 |  |  |
Outstanding, June 30, 2014 |  | 4,343,334 |  | $ | 3.61 |  | 5.6 |
Exercisable at June 30, 2014 |  | 1,387,871 |  | $ | 4.33 |  | 4.0 |
Schedule Of Warrants Issued To Agents Activity [Table Text Block] | AntriaBio issued warrants to agents and note holders in conjunction with the closing of its convertible notes payable and equity financings as follows:
|  |  |  | Weighted |  | Weighted Average |
|  | Number of |  | Average |  | Remaining |
|  | Warrants |  | Exercise Price |  | Contractual Life |
Outstanding, June 30, 2013 |  |  | 293,092 |  | $ | 2.21 |  |  | 4.1 |
Warrants issued to note holders |  |  | 225,259 |  | $ | 1.89 |  |  |  |
Warrants issued to note holders |  |  | 4,039,184 |  | $ | 1.98 |  |  |  |
Warrants issued to related party |  |  | 39,117 |  | $ | 7.50 |  |  |  |
Warrants issued in private placement |  |  | 6,287,679 |  | $ | 2.34 |  |  |  |
Warrants issued to placement agent |  |  | 290,861 |  | $ | 1.56 |  |  |  |
Warrants issued for investor relations |  |  | 66,667 |  | $ | 3.34 |  |  |  |
Warrants exercised |  |  | (100,550) |  | $ | 1.17 |  |  |  |
Warrants forfeited |  |  | (41,570) |  | $ | 1.17 |  |  |  |
Outstanding, June 30, 2014 |  |  | 11,099,739 |  | $ | 2.21 |  |  | 3.6 |
Warrants issued in private placements |  |  | 5,276,280 |  | $ | 2.50 |  |  |  |
Warrants issued to placement agent |  |  | 1,576,937 |  | $ | 2.50 |  |  |  |
Warrants issued for investor relations |  |  | 105,000 |  | $ | 1.65 |  |  |  |
Warrants cancelled |  |  | (59,758) |  | $ | 2.92 |  |  |  |
Outstanding, March 31, 2015 |  |  | 17,998,198 |  | $ | 2.31 |  |  | 3.0 |
| Warrants- AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows:
|  |  |  | Weighted |  | Weighted Average |
|  | Number of |  | Average |  | Remaining |
|  | Warrants |  | Exercise Price |  | Contractual Life |
Outstanding, June 30, 2012 |  | - |  | $ | - |  | - |
Warrants issued to placement agents |  | 41,424 |  | $ | 2.03 |  |  |
Warrants issued to placement agent |  | 233,334 |  | $ | 2.03 |  |  |
Warrants issued to placement agent |  | 18,334 |  | $ | 4.95 |  |  |
Outstanding, June 30, 2013 |  | 293,092 |  | $ | 2.21 |  | 4.1 |
Warrants issued to note holders |  | 225,259 |  | $ | 1.89 |  |  |
Warrants issued to note holders |  | 4,039,184 |  | $ | 1.98 |  |  |
Warrants issued to related party |  | 39,117 |  | $ | 7.50 |  |  |
Warrants issued in private placement |  | 6,287,679 |  | $ | 2.34 |  |  |
Warrants issued to placement agent |  | 290,861 |  | $ | 1.56 |  |  |
Warrants issued for invest or relations |  | 66,667 |  | $ | 3.34 |  |  |
Warrants exercised |  | (100,550) |  | $ | 1.17 |  |  |
Warrants forfeited |  | (41,570) |  | $ | 1.17 |  |  |
Outstanding, June 30, 2014 |  | 11,099,739 |  | $ | 2.21 |  | 3.6 |
Black Scholes Pricing Model |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2015 using the following assumptions:
Expected volatility |  |  | 90 - 92 | %
Risk free interest rate |  |  | 1.31% - 1.88 | %
Expected term (years) |  |  | 5 - 7 |
Dividend yield |  |  | 0 | %
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] | The estimated fair value was derived using the lattice model with the following assumptions:
Expected volatility |  |  | 93 | %
Risk free interest rate |  |  | 2.21 | %
Warrant term (years) |  |  | 7 |
Dividend yield |  |  | 0 | %
| Significant assumptions were as follows:
Expected volatility |  | 92% - 97 | %
Risk free interest rate |  | 0.78% - 2.21 | %
Contractual term (years) |  | 3 - 7 |
Dividend yield |  | 0 | %
Lattice Model |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] |  | The estimated fair value was derived using the lattice model with the following assumptions:
Expected volatility |  | 93 | %
Risk free interest rate |  | 2.21 | %
Contractual term (years) |  | 7 |
Dividend yield |  | 0 | %
Lattice Model One |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] | The estimated fair value was derived using the lattice model with the following assumptions:
Expected volatility |  |  | 90% - 91 | %
Risk free interest rate |  |  | 1.89% - 1.98 | %
Warrant term (years) |  |  | 7 |
Dividend yield |  |  | 0 | %
Lattice Model Two |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] | The estimated fair value was derived using the lattice model with the following assumptions:
Expected volatility |  |  | 90 | %
Risk free interest rate |  |  | 1.71 | %
Warrant term (years) |  |  | 7 |
Dividend yield |  |  | 0 | %
Black Scholes Valuation Model |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions were as follows:
Expected volatility |  |  | 89% - 97 | %
Risk free interest rate |  |  | 0.56% - 2.21 | %
Warrant term (years) |  |  | 2 - 7 |
Dividend yield |  |  | 0 | %

X
- Definition Schedule of share based payment award stock warrants valuation assumptions [Table Text Block] + References No definition available. + Details
Name: | antb_ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock
Namespace Prefix: | antb_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants issued to agents and note holders in conjunction with the closing of its convertible notes payable and equity financings. + References No definition available. + Details
Name: | antb_ScheduleOfWarrantsIssuedToAgentsActivityTableTextBlock
Namespace Prefix: | antb_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=antb_BlackScholesPricingModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=antb_BlackScholesValuationModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=antb_LatticeModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=antb_LatticeModelOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=antb_LatticeModelTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |